Supplementary Table 1: Allele distribution and demographic characteristics by ancestry
Cohort Ancestry Total
% Female
Age of Onset
CCR5-Delta32 Heterozygotes
CCR5-Delta32 Homozygotes
%Delta32 Alleles
AD European 428 50.9 62.6 ±10.4 75 (17.5%) 7 (1.64%) 10.40
African 8 62.5 . 1 (12.5%) 0 (0%) 6.25
Asian 50 56.0 66.6±10.1 0 (0%) 0 (0%) .
Mixed 9 33.3 . 0 (0%) 0 (0%) .
FTD European 348 43.7 57.5 ±10.0 61 (17.5%) 4 (1.15%) 9.91
African 3 100.0 . 0 (0%) 0 (0%) 0.00
Asian 13 53.8 . 1 (7.7%) 0 (0%) 3.85
Mixed 9 33.3 . 0 (0%) 0 (0%) .
MCI European 196 47.4 62.8 ±9.1 44 (22.4%) 3 (1.53%) 12.76
African 3 66.7 . 0 (0%) 0 (0%) .
Asian 54 61.1 63.4±7.3 1 (1.9%) 0 (0%) 0.93
Mixed 6 50.0 . 1 (16.7%) 0 (0%) 8.33
PSP-S European 82 48.8 64.2 ±7.2 12 (14.6%) 3 (3.66%) 10.98
African 1 0.0 . 0 (0%) 0 (0%) .
Asian 7 57.1 . 0 (0%) 0 (0%) .
Mixed 5 20.0 . 0 (0%) 1 (20.0%) 20.00
CBS European 62 56.5 60.1 ±7.7 10 (16.1%) 4 (6.45%) 14.52
African 4 75.0 . 1 (25.0%) 0 (0%) 12.5
Asian 5 40.0 . 0 (0%) 0 (0%) .
Mixed 0 . . . . .
ALS European 19 36.8 49.6 ±15.6 3 (15.8%) 0 (0%) 7.89
African 0 . . . . .
Asian 3 33.3 . 0 (0%) 0 (0%) .
Mixed 1 0.0 . 1 (100%) 0 (0%) 50.0
Overall European 1135 48.0 60.8 ±10.2 205 (18.1%) 21 (1.85%) 10.88
African 19 68.4 . 2 (10.5%) 0 (0%) 5.26
Asian 132 56.8 62.9±9.0 2 (1.5%) 0 (0%) 0.76
Mixed 30 33.3 61.6±10.9 2 (6.7%) 1 (3.3%) 6.67
Controls European 1251 54.0 N/A 251 (20.1%) 22 (1.76%) 11.79
African 356 64.0 N/A 26 (7.3%) 0 (0%) 3.65
Asian 66 66.7 N/A 5 (7.6%) 1 (1.5%) 5.30
Mixed 11 54.5 N/A 0 (0%) 0 (0%) .
AD: Alzheimer’s disease, FTD: frontotemporal dementia, MCI: mild cognitive impairment, PSP-S:
progressive supranuclear palsy syndrome, CBS: corticobasal syndrome, ALS: amyotrophic lateral sclerosis. Overall refers to the combined neurodegenerative patient samples.
Average age of onset was only calculated for groups with data available on 5 or more patients. Within the European cohorts age of onset was available in: AD (163/428), FTD (115/348), MCI (42/196), PSP-S (23/82), CBS (20/62), ALS (5/19).
Gender was available all samples.
Ancestry was available for 1316 patients and 1684 controls.